期刊论文详细信息
Diagnostic Pathology
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
Karin Jirström2  Anders Bjartell1  Mathias Uhlén3  David Ulmert1  Alexander Gaber2  Liv Jonsson2 
[1] Department of Clinical Sciences, Division of Urological Cancers, Lund University, Skåne University Hospital, 205 02 Malmö, Sweden;Department of Clinical Sciences, Pathology, Lund University, Skåne University Hospital, 221 85 Lund, Sweden;Science for Life Laboratory, Royal Institute of Technology, 106 91 Stockholm, Sweden
关键词: prostate cancer;    prognosis;    immunohistochemistry;    RBM3;   
Others  :  808240
DOI  :  10.1186/1746-1596-6-91
 received in 2011-08-31, accepted in 2011-09-28,  发布年份 2011
PDF
【 摘 要 】

Background

High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer.

Findings

Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression).

Conclusion

Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.

【 授权许可】

   
2011 Jonsson et al; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140708151144757.pdf 3267KB PDF download
Figure 4. 61KB Image download
Figure 3. 56KB Image download
Figure 2. 28KB Image download
Figure 1. 144KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】
  • [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
  • [2]Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781.
  • [3]Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364(18):1708-1717.
  • [4]Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
  • [5]Bjartell A, Montironi R, Berney DM, Egevad L: Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011, 50(Suppl 1):76-84.
  • [6]Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A: Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011, 50(Suppl 1):61-75.
  • [7]Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, Matsuda T, Fujita J: Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun 1997, 236(3):804-807.
  • [8]Lleonart ME: A new generation of proto-oncogenes: cold-inducible RNA binding proteins. Biochim Biophys Acta 2010, 1805(1):43-52.
  • [9]Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, et al.: Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene 2008, 27(33):4544-4556.
  • [10]Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Buhrer C: The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res 2010, 67(1):35-41.
  • [11]Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, et al.: Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol 2009, 22(12):1564-1574.
  • [12]Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, et al.: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005, 4(12):1920-1932.
  • [13]Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, Uhlen M, Ponten F: A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics 2008, 7(5):825-844.
  • [14]Ponten F, Jirstrom K, Uhlen M: The Human Protein Atlas--a tool for pathology. J Pathol 2008, 216(4):387-393.
  • [15]Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al.: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010, 8:78. BioMed Central Full Text
  • [16]Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M, Jirstrom K: Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmo Diet and Cancer Study. J Transl Med 2011, 9(1):114. BioMed Central Full Text
  • [17]Ehlen O, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K: RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Transl Oncol 2011, 4(4):212-221.
  • [18]Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, et al.: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007, 177(2):540-545.
  • [19]Zeng Y, Kulkarni P, Inoue T, Getzenberg RH: Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem 2009, 107(1):179-188.
  • [20]Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23(3):609-618.
  • [21]Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J: DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl 2007, 30(4):282-291. discussion 291
  • [22]Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al.: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434(7035):864-870.
  • [23]Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al.: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434(7035):907-913.
  文献评价指标  
  下载次数:118次 浏览次数:22次